You searched for "obstruction"
MRI screening for prostate cancer: a step towards a ‘prostagram’
The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...Lasers in urology
1. What does LASER stand for? 2. What elements are involved and how is a LASER created? 3. The following cases involve laser surgery. Can you diagnose the pathology, identify which type of lasers can be used, and their wavelengths?...A report from the second laparoscopic urology workshop in Dakar, Senegal
Hôpital Général Idrissa Pouye (HOGIP), formerly Hôpital Général de Grand Yoff – HOGGY), in Dakar, Senegal, is one of the most well-regarded teaching hospitals in West Africa. It has over 300 beds, a urology team of six consultants and attracts...NOVOGLAN – Conservative Phimosis Management
iMEDicare are pleased to introduce Novoglan, an evidence-based, non-surgical solution for adult phimosis, now available as a reimbursable outpatient treatment under the NHS OPCS-4 code N30.5 (Stretching of the Prepuce), which maps to HRG LB56A. This presents an exciting opportunity...
Pre-transplant management of valve bladder
This paper examines the evidence concerning the timing, indications and problems associated with augmentation cystoplasty (AC), posterior urethral valves (PUV), and end stage renal failure (ESRF) using a literature review via Medline, Cochrane library and LILACS databases. Two search strategies...Coloplast: MS Masterclass
@09.30 am - 04.00 pmProstate cancer management 2 – metastatic disease
A 72-year-old gentleman is referred to you in the two-week wait clinic with a prostate specific antigen (PSA) of 22ug/L. He is otherwise fit and well and does not take any regular medication. His multi-parametric magnetic resonance imaging (mpMRI) shows...Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...The Parnell Fund Bursary 2019
At the start of July 2019 applications for the Parnell Fund Bursary were opened to trainees, consultants and healthcare professionals across the United Kingdom with an interest in female, functional and neuro-urology. Rachel Barratt, who was awarded the Parnell Fund...Bladder cancer: where are we with intravesical therapies?
In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...
